Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutrate vs Enantone PK/PD in Healthy Males
NCT03662958Phase 1Unknown
- Sponsor
- Lee's Pharmaceutical Holdings Limited
- Start
- Aug 2018
- Primary completion
- Oct 2018
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of TOL-2506 in prostate cancer (PCa) (2 arms), sponsored by Lee's Pharmaceutical Holdings Limited. Primary endpoint: Rate of castration at 4 weeks. Status: unknown.
02
Drugs
TOL-2506
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03662958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03662958.